Foresite Capital Management III as of Sept. 30, 2016
Portfolio Holdings for Foresite Capital Management III
Foresite Capital Management III holds 17 positions in its portfolio as reported in the September 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Aerie Pharmaceuticals | 29.9 | $64M | 1.7M | 37.74 | |
| Alder Biopharmaceuticals | 24.3 | $52M | 1.6M | 32.77 | |
| Wave Life Sciences (WVE) | 11.0 | $24M | 728k | 32.47 | |
| Aimmune Therapeutics | 6.6 | $14M | 935k | 15.00 | |
| Intellia Therapeutics (NTLA) | 6.1 | $13M | 764k | 17.02 | |
| Global Blood Therapeutics In | 4.9 | $11M | 456k | 23.05 | |
| Nanostring Technologies (NSTGQ) | 4.5 | $9.7M | 486k | 19.98 | |
| Momenta Pharmaceuticals | 3.2 | $7.0M | 596k | 11.69 | |
| Protagonist Therapeutics (PTGX) | 2.9 | $6.3M | 346k | 18.15 | |
| Epizyme | 2.8 | $6.0M | 612k | 9.84 | |
| Zafgen | 0.8 | $1.8M | 538k | 3.31 | |
| Akari Therapeutics | 0.8 | $1.7M | 197k | 8.51 | |
| Lipocine | 0.6 | $1.3M | 303k | 4.46 | |
| Audentes Therapeutics | 0.6 | $1.2M | 67k | 17.81 | |
| Orexigen Therapeutics | 0.4 | $844k | 254k | 3.32 | |
| Syros Pharmaceuticals | 0.4 | $832k | 60k | 13.87 | |
| BioDelivery Sciences International | 0.1 | $127k | 47k | 2.69 |
